Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
argenx SE
ARGX · SEC Filings
website
1.9K
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated ...
Price
962.27
Market Cap
59.72 B
Float
61.94 M
Country
NL
Sector
Healthcare
Exchange
NASDAQ
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about ARGX
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
argenx SE
ARGX · SEC Filings
61.94 M
Float
962.27
Price
59.72 B
Market Cap
Financials
TYPE
HEADLINE
FILED AT
News
TYPE
HEADLINE
FILED AT
6-K
NEW
argenx Presents Phase 3 ALKIVIA Data Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis
Nov 9, 2026
6-K
NEW
argenx to Acquire Unnatural Products, Inc. for up to $1.15 Billion to Expand Immunology Capabilities
Nov 9, 2026
6-K
argenx Reports Third Quarter 2026 Financial Results with $1.7 Billion in Global Product Net Sales
Oct 22, 2026
6-K
argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026
Oct 19, 2026
6-K
argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
Oct 8, 2026
6-K
argenx Presents New Clinical and Real-World Data Highlighting VYVGART and Pipeline Progress at AANEM and MGFA Meetings
Sep 29, 2026
Prospectus
TYPE
HEADLINE
FILED AT
424B5
2,244,899 Ordinary shares
Jul 20, 2023
424B5
$750,000,000
Jul 17, 2023
424B5
2,333,334 Ordinary shares
Mar 25, 2022
424B5
$500,000,000
Mar 22, 2022
424B5
3,125,000 Ordinary shares-
Feb 4, 2021
424B5
$750,000,000-
Feb 1, 2021
Registrations
TYPE
HEADLINE
FILED AT
SC TO-T/A
Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
Aug 27, 2026
SC TO-T/A
Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
Aug 19, 2026
SC TO-T/A
Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
Aug 6, 2026
SC TO-T
Form SC TO-T - Tender offer statement by Third Party
Aug 6, 2026
SC TO-C
argenx to Acquire Forte Biosciences for $2.2 Billion
Jul 28, 2026
SC TO-C
argenx to Acquire Forte Biosciences, Inc. for $2.2 Billion
Jul 27, 2026
Proxies
TYPE
HEADLINE
FILED AT
Ownerships
TYPE
HEADLINE
FILED AT
SCHEDULE 13G/A
FMR LLC (Filed by)
Nov 5, 2026
SCHEDULE 13G/A
PRICE T ROWE ASSOCIATES INC /MD/ (Filed by)
Aug 14, 2026
SCHEDULE 13G/A
FMR LLC (Filed by)
May 6, 2026
SCHEDULE 13G/A
PRICE T ROWE ASSOCIATES INC /MD/ (Filed by)
Nov 14, 2025
SCHEDULE 13G/A
PRICE T ROWE ASSOCIATES INC /MD/ (Filed by)
Aug 14, 2025
SCHEDULE 13G/A
Artisan Partners Limited Partnership (Filed by)
Aug 12, 2025
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
LETTER
Form UPLOAD - SEC-generated letter
Dec 18, 2025
CORRESP
Form CORRESP - Correspondence
Sep 25, 2025
LETTER
Form UPLOAD - SEC-generated letter
Aug 25, 2025
CT ORDER
Form CT ORDER - Confidential treatment order
May 9, 2019
EFFECT
Form EFFECT - Notice of Effectiveness
Dec 14, 2017
CORRESP
Form CORRESP - Correspondence
Dec 11, 2017
